Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Best practices in outpatient opioid stewardship include a consistent framework: baseline and periodic risk assessment (e.g., validated tools, history of substance use), PDMP review at initiation and at defined intervals, and an opioid treatment agreement outlining expectations, safe storage, and refill policies. Co-prescribing naloxone for patients on higher morphine milligram equivalents or with risk factors improves safety without implying misuse. Documenting measurable functional goals (sleep, activity, participation) guides dose adjustments and tapering decisions. Urine drug testing can be used judiciously. Rigid visit requirements (Option C) may limit access; telehealth with periodic in-person assessment can be risk-stratified. Skipping PDMP checks (Option A) contravenes safety standards and many state regulations. Avoiding naloxone (Option D) contradicts harm-reduction principles. APRNs should integrate multimodal analgesia, monitor for adverse effects, and coordinate with palliative care and behavioral health, balancing analgesia with function and safety while meeting documentation and regulatory expectations.

Immune checkpoint inhibitor (ICI)–related colitis is a common immune-related adverse event (irAE), typically presenting with diarrhea, cramping, and sometimes blood or mucus. Grade 3 toxicity (≥7 stools/day over baseline or severe symptoms) warrants holding the ICI and initiating high-dose corticosteroids (e.g., methylprednisolone 1–2 mg/kg/day IV or equivalent oral dosing if stable). Infectious etiologies (C. difficile, stool cultures) should be ruled out but therapy should not be unduly delayed in a clinically consistent scenario. If no improvement within 48–72 hours, escalation to infliximab or vedolizumab is recommended, with careful evaluation for perforation/toxic megacolon. Option A is inadequate for grade ≥2 colitis. Permanent discontinuation (Option C) is considered for life-threatening or steroid-refractory events; budesonide targets mild ileocolonic disease and is insufficient here. Octreotide (Option D) is not standard for ICI colitis. Patient education on symptom recognition, early reporting, hydration, and a stepwise steroid taper over at least 4–6 weeks to prevent rebound symptoms is integral to supportive care.

Quality improvement (QI) aims to enhance local care processes within accepted standards, using rapid-cycle testing (PDSA) and operational metrics (e.g., 30-day ED visits). When interventions are evidence-based and the intent is internal improvement rather than generating generalizable knowledge, many institutions do not require formal IRB review—though privacy protections and governance still apply. However, boundaries can blur: if a project includes randomization, novel interventions, or plans to publish as research beyond typical QI reporting, IRB consultation may be necessary. Therefore, best practice is to submit a determination request to your IRB or QI office for classification. Assuming all data use mandates IRB (Option A/C) overregulates QI and can impede timely care improvements. Declaring QI never needs oversight (Option D) ignores institutional policies for data security/HIPAA, risk review, and ethical considerations. APRNs should define aims, measures, and methods clearly; secure appropriate approvals; ensure data de-identification where possible; and transparently communicate results within the health system.

Cancer-related fatigue (CRF) is multifactorial and best addressed with a multimodal approach. High-quality evidence supports supervised or home-based aerobic and resistance training to improve fatigue, function, and quality of life. Sleep disturbance perpetuates CRF; cognitive behavioral therapy for insomnia (CBT-I) and structured sleep hygiene (consistent schedule, stimulus control, limiting late caffeine, light exposure) are core components. Concurrently, evaluate and treat reversible contributors—anemia, thyroid dysfunction, pain, depression/anxiety, medication effects (e.g., sedating agents), deconditioning, and nutritional deficits. Teach energy-conservation strategies (prioritize tasks, pacing, planned rest) and consider referral to rehabilitation. Stimulants may have a role for select patients after nonpharmacologic measures are optimized, but evidence is mixed and side effects are common; they should not be first-line. Routine high-dose vitamins/herbals lack evidence and may interact with therapies. Delaying action risks entrenching deconditioning. The APRN coordinates referrals (rehab, sleep medicine, psycho-oncology), sets measurable goals (step counts, strength milestones), and schedules follow-up to adjust the plan based on patient-reported outcomes.

Biobanking involves altruistic donation for unspecified future research and demands robust informed consent. Key elements include a clear description of purpose, specimen types, potential future uses (including genetic analyses), governance/ownership, privacy protections (coding/de-identification), data sharing (e.g., with collaborators/consortia), commercial use possibilities, and policies on return of results/incidental findings (often not guaranteed). Consent should explain voluntariness, lack of direct benefit, and the right to withdraw specimens not yet used—recognizing that data from completed studies cannot usually be retracted. Opt-out or implied consent (Options A/C) fails ethical standards. Promising all individual results (Option D) is unrealistic; plans typically specify when clinically actionable findings may be returned. APRNs ensure comprehension with plain language and teach-back, offer time for questions, and document decisional capacity. They also coordinate with research offices for proper specimen handling, maintain separation between clinical care and research decisions, and avoid undue influence during vulnerable moments (e.g., acute diagnosis discussions).